Kathryn C Zoon insider trades: Emergent BioSolutions (EBS) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Kathryn reports to the SEC
Open-market buys and sales
22 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | EBS | ↓ Sell10b5-1 | 17,202 | $8.40 | $144K | Direct | May 4, 2026 (3d) |
| Aug 15, 2025 | EBS | ↓ Sell10b5-1 | 7,086 | $8.87 | $63K | Direct | Aug 18, 2025 (3d) |
| Mar 12, 2025 | EBS | ↓ Sell | 10,000 | $5.73 | $57K | Direct | Mar 12, 2025 (0d) |
| Jun 4, 2024 | EBS | ↓ Sell | 10,000 | $6.11 | $61K | Direct | Jun 6, 2024 (2d) |
| May 29, 2024 | EBS | ↓ Sell | 1,830 | $4.61 | $8K | Direct | May 31, 2024 (2d) |
| May 21, 2024 | EBS | ↓ Sell | 1,089 | $5.78 | $6K | Direct | May 23, 2024 (2d) |
| Jun 2, 2023 | EBS | ↓ Sell10b5-1 | 3,530 | $8.36 | $30K | Direct | Jul 24, 2023 (52d) |
| Jun 9, 2022 | EBS | ↓ Sell | 1,173 | $31.52 | $37K | Direct | Jun 13, 2022 (4d) |
| May 24, 2022 | EBS | ↓ Sell | 1,996 | $35.53 | $71K | Direct | May 25, 2022 (1d) |
| May 25, 2021 | EBS | ↓ Sell | 3,139 | $56.48 | $177K | Direct | May 27, 2021 (2d) |
| Aug 10, 2020 | EBS | ↓ Sell | 1,000 | $130.27 | $130K | Direct | Aug 11, 2020 (1d) |
| May 26, 2020 | EBS | ↓ Sell10b5-1 | 4,093 | $85.10 | $348K | Direct | May 27, 2020 (1d) |
| May 12, 2020 | EBS | ↓ Sell | 1,660 | $85.21 | $141K | Direct | May 14, 2020 (2d) |
| Mar 4, 2020 | EBS | ↓ Sell | 991 | $60.65 | $60K | Direct | Mar 6, 2020 (2d) |
| Nov 18, 2019 | EBS | ↓ Sell | 1,000 | $54.31 | $54K | Direct | Nov 19, 2019 (1d) |
| Nov 8, 2019 | EBS | ↓ Sell10b5-1 | 3,082 | $54.15 | $167K | Direct | Nov 12, 2019 (4d) |
| Sep 9, 2019 | EBS | ↓ Sell | 1,509 | $56.12 | $85K | Direct | Sep 10, 2019 (1d) |
| May 28, 2019 | EBS | ↓ Sell10b5-1 | 1,376 | $43.39 | $60K | Direct | May 28, 2019 (0d) |
| Nov 7, 2018 | EBS | ↓ Sell10b5-1 | 4,242 | $69.74 | $296K | Direct | Nov 8, 2018 (1d) |
| Jun 6, 2018 | EBS | ↓ Sell | 376 | $52.81 | $20K | Direct | Jun 7, 2018 (1d) |
| May 24, 2018 | EBS | ↓ Sell10b5-1 | 1,377 | $51.15 | $70K | Direct | May 29, 2018 (5d) |
| Nov 8, 2017 | EBS | ↓ Sell10b5-1 | 2,742 | $39.20 | $107K | Direct | Nov 13, 2017 (5d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other EBS insiders
Open-market trades in the last 12 months
About Kathryn C Zoon's insider trades
Kathryn C Zoon is a director at Emergent BioSolutions (EBS). Since Nov 8, 2017, Kathryn has reported no open-market purchases and 22 sales worth $2.2M on SEC Form 4. In the last 12 months: 1 sale ($144K).
9 sales (59% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (11 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every EBS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.